NAICS : 325412
SIC : 2836
Traded in other countries
200 Technology Square, 4th Floor, Cambridge, MA, USA, 02139
Proteostasis Therapeutics Inc is a United States-based company engaged in the biotechnology industry. Its core operations comprise of discovery and development of therapeutics that treat diseases caused by an imbalance in protein biosynthesis process in the body. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics. Using this platform, it has identified a new class of small molecules and amplifiers that modulate proteins in the proteostasis network. The products under its development cycle include PTI-428, which is a lead amplifier of CFTR protein. It also focuses on developing PTI-NC-733, PTI-130, Usp14 program and unfolded protein response (UPR) program.